Everence Capital Management Inc. Purchases Shares of 26,350 Avantor, Inc. (NYSE:AVTR)

Everence Capital Management Inc. purchased a new position in Avantor, Inc. (NYSE:AVTR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 26,350 shares of the company's stock, valued at approximately $555,000.

Other institutional investors have also made changes to their positions in the company. UMB Bank n.a. acquired a new position in Avantor in the 3rd quarter worth about $49,000. Nisa Investment Advisors LLC increased its holdings in Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock worth $53,000 after buying an additional 835 shares during the last quarter. GAMMA Investing LLC raised its position in Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock valued at $70,000 after acquiring an additional 1,285 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its position in Avantor by 278.0% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company's stock valued at $130,000 after acquiring an additional 3,700 shares in the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in Avantor in the third quarter valued at approximately $139,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AVTR. UBS Group dropped their price target on shares of Avantor from $30.00 to $29.00 and set a "buy" rating on the stock in a research note on Tuesday, October 8th. Wells Fargo & Company lowered their target price on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Monday, October 28th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $34.00 price target on shares of Avantor in a research report on Thursday, September 26th. Barclays lowered their price objective on Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday, October 25th. Finally, Robert W. Baird reduced their target price on Avantor from $27.00 to $26.00 and set an "outperform" rating for the company in a report on Monday, October 28th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.69.

Avantor Stock Performance

AVTR stock traded up $0.56 on Friday, reaching $21.76. 2,485,287 shares of the company were exchanged, compared to its average volume of 2,570,244. The firm has a market capitalization of $14.81 billion, a PE ratio of 47.30, a PEG ratio of 2.75 and a beta of 1.28. Avantor, Inc. has a 12 month low of $19.59 and a 12 month high of $28.00. The stock's fifty day moving average price is $21.57 and its 200 day moving average price is $23.34. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.